Patents by Inventor David O. Azorsa

David O. Azorsa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hybridoma clones and monoclonal antibodies to ING4
    Patent number: 9193785
    Abstract: The present invention is directed to a monoclonal antibody that recognizes human ING4 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and to methods of diagnosing cancer using the antibody.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: November 24, 2015
    Assignees: The Translational Genomics Research Institute, The Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: David O. Azorsa, Suwon Kim
  • HYBRIDOMA CLONES AND MONOCLONAL ANTIBODIES TO ING4
    Publication number: 20140113834
    Abstract: The present invention is directed to a monoclonal antibody that recognizes human ING4 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and to methods of diagnosing cancer using the antibody.
    Type: Application
    Filed: October 22, 2013
    Publication date: April 24, 2014
    Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventors: David O. Azorsa, Suwon Kim
  • Compositions and Methods for Prognosis, Diagnosis, Prevention and Treatment of Cancers
    Publication number: 20100120025
    Abstract: The present invention provides compositions and methods of using the EPHB2 gene or its related signaling pathways to detect, prognosticate, assess the risk of, prevent, or treat cancers. Cancers amenable to the present invention include, but are not limited to, prostate cancer, breast cancer, and neuroblastoma. In one aspect, the present invention provides compositions which comprise an agent capable of eradicating or alleviating an abnormality in the EPHB2 gene or its related signaling pathways. This abnormality may cause or contribute to the development or progression of cancers. In another aspect, the present invention provides methods comprising detecting an abnormality in the EPHB2 gene or its related signaling pathways. The presence or absence of such an abnormality is indicative of the risk or disease status of cancer in a person of interest.
    Type: Application
    Filed: June 13, 2008
    Publication date: May 13, 2010
    Applicant: TGEN
    Inventors: Spyro Mousses, Pia Huusko, Olli-P Kallioniemi, John D. Carpten, David O. Azorsa, Jeffrey Kiefer
  • Compositions and methods for prognosis of cancers
    Patent number: 7402389
    Abstract: The present invention provides compositions and methods of using the EPHB2 gene or its related signaling pathways to detect, prognosticate, assess the risk of, prevent, or treat cancers. Cancers amenable to the present invention include, but are not limited to, prostate cancer, breast cancer, and neuroblastoma. In one aspect, the present invention provides compositions which comprise an agent capable of eradicating or alleviating an abnormality in the EPHB2 gene or its related signaling pathways. This abnormality may cause or contribute to the development or progression of cancers. In another aspect, the present invention provides methods comprising detecting an abnormality in the EPHB2 gene or its related signaling pathways. The presence or absence of such an abnormality is indicative of the risk or disease status of cancer in a person of interest.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: July 22, 2008
    Assignee: The Translational Genomics Research Institute (TGen)
    Inventors: Spyro Mousses, Pia Huusko, Olli Kallioniemi, John D. Carpten, David O. Azorsa, Jeffrey Kiefer